Patient P-01782

Synthetic patientNBL-101 · Day 100 · 65–74 · M · baseline S14Steering view · 3D Open companion preview

Therapy response

Stable

Tolerance

Favorable

GI state

Stable

Inflammatory state

Stable

Nutritional resilience

Declining

Discontinuation risk

85%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events

solid = observed · dashed = predicted

Day 0 NBL-101 started — Baseline state S14
Day 31 NP-02 recommended — Dietary Support Protocol NP-02
Day 32 Patient accepted — Started NP-02 in the companion
Day 42 No meaningful change — Dietary Support Protocol NP-02
Day 48 SC-12 recommended — Supportive Compound SC-12
Day 49 Patient accepted — Started SC-12 in the companion
Day 51 Trajectory diverged from prediction — Observed response fell below the model's expected path.
Day 55 No meaningful change — Supportive Compound SC-12
Day 64 ME-01 recommended — Monitoring Escalation ME-01
Day 65 Patient accepted — Started ME-01 in the companion
Day 68 Deterioration detected before clinical escalation — Monitoring Escalation ME-01

What changed?

Trajectory began diverging from predicted response on Day 51.

Primary contributors, last 14 days

Nutritional resilience-8
Treatment adherence+5
Inflammatory activity+3
GI instability+2

What helped?

Dietary Support Protocol NP-02Day 31
Result: no meaningful change
Supportive Compound SC-12Day 48
Result: no meaningful change
Monitoring Escalation ME-01Day 64
Result: deterioration detected before clinical escalation

LIFE OS recommendation

GI Support Protocol GI-04

86%

probability of meaningful tolerance improvement

284 similar trajectories
83% showed improvement
median effect visible after 8 days

Daily trackers

Molecule settings

The trackers this program marks as important, last 14 days vs the 14 before.

GI burden

Companion

52.8/100

stable · -0.5 vs previous 14 d

Toxicity

Blood

39.7/100

improving · -7.1 vs previous 14 d

Sleep quality

Wearable

34/100

stable · -0.7 vs previous 14 d

Energy level

Daily log

3.4/10

stable · -0.1 vs previous 14 d

Stress level

Daily log

5.8/10

improving · -0.5 vs previous 14 d

Steps

Wearable

1,468

worsening · -231 vs previous 14 d

Adherence

Companion

49.1 %

stable · -0.6 vs previous 14 d

This trajectory is decaying — what would help, what would not

Steering view →

Heading towards failing · 34 from the failing basin, 54 from restoration.

Would help

GI-04 GI Support Protocol
73% improved among 124 similar · onset 8 d · confidence 89%
CR-01 Clinician Review
100% improved among 8 similar · onset 5 d · confidence 72%

Would not help

NP-02 Dietary Support Protocol
already tried, no meaningful change
SC-12 Supportive Compound
already tried, no meaningful change
Keep fat low
GI +4.9 next day on high-intake days · n 27
Keep histamine low
GI +3.4 next day on high-intake days · n 20
Keep simple carbs low
GI +3.1 next day on high-intake days · n 14

State influencers · digestive

Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.

Dietary fat load
+4.9detractor · 95%
Histamine load
+3.4detractor · 95%
Simple carbohydrates
+3.1detractor · 89%
Spicy / capsaicin
+2.9detractor · 88%
Insoluble fibre
+1.4no signal · 37%
Alcohol
+0.9no signal · 23%

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure

Mucosal barrier integrity ↓80
- DNAFUT2 non-secretor lowers mucosal fucosylation
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 53 and rising
Butyrate / short-chain fatty acid production ↓80
- MicrobiomeButyrate capacity 38/100
- MicrobiomeF. prausnitzii depleted
- Daily logFibre intake low in recent food logs
Inflammatory signalling ↑70
- DNAIL6 -174 variant raises baseline inflammatory tone
- MicrobiomeBacteroides fragilis expansion
- BloodInflammatory load index 50
Autonomic recovery ↓45
- WearableResting HR 83 bpm
- Wearable1,468 steps/day

DNA

Fictional pharmacogenomic panel

FUT2 rs601338 AA (non-secretor)
Reduced mucosal fucosylation
IL6 -174 G/C
Higher inflammatory tone
CYP2D6 Intermediate metabolizer
Expected exposure

Microbiome

Shannon diversity 2.5 · butyrate capacity 38/100

Akkermansia muciniphilaLow
Faecalibacterium prausnitziiLow
Bacteroides fragilisHigh
Bifidobacterium longumNormal
EnterobacteriaceaeNormal

Wearable, last 14 days

daily evolution fed into the runtime

HRV: 39 ms
Sleep: 6.6 h
Steps: 1,762
Resting HR: 84 bpm

Daily log: GI score 53, nutritional resilience 43, adherence 49.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview

What to eat

Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
Avoid known triggers for now: fried or oily food, dairy, alcohol

What to do

Track each bowel movement today: time, stool form, urgency, overnight waking
A 15-minute walk after lunch
Keep the sleep window steady
Keep hydration steady: small amounts through the day rather than large volumes at once

What to take

Take the scheduled dose as agreed with your care team
Electrolyte solution, one sachet after any loose stool
Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

Patient	Similarity	Baseline	Intervention	Outcome	Response today
P-01327	48%	S01	GI-04	improved	56
P-01813	37%	S01	NP-02	no change	40
P-01688	35%	S01	GI-04	improved	40
P-01310	30%	S01	—	—	57
P-01877	25%	S01	CR-01	improved	67
P-01821	22%	S01	—	—	58
P-01604	21%	S01	—	—	71
P-01823	21%	S01	—	—	57
P-01452	38%	S02	GI-04	improved	46
P-01635	38%	S02	GI-04	improved	49
P-01459	27%	S02	—	—	51
P-01498	22%	S02	—	—	56